Findings

What do systematic reviews say?

4 questions · 4 findings · 3 reviews

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 1 · 25%Low 1 · 25%Moderate 1 · 25%High 0 · 0%

Serious adverse events · People with quiescent Crohn's disease (ileocolic resection)

The review found no eligible studies for this question.

1 finding from 1 review

Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events · Participants with Crohn's disease in remission

Adalimumab probably leads to lower serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Adalimumab for maintenance of remission in Crohn's disease 2020 · Cochrane Headline outcomes only
RR 0.56 [0.39, 0.8]
4 studies · 1012 participants
Moderate

Serious adverse events · Patients with active Crohn's disease

The intervention showed no clear difference in serious adverse events (low certainty).

1 finding from 1 review

Adalimumab for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.44 [0.17, 1.15]
3 studies · 531 participants
Low

Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)

It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 0.09 [0.01, 1.54]
1 study · 73 participants
Very low